Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Dovitinib |
Trade Name | |
Synonyms | TKI258|CHIR-258 |
Drug Descriptions |
Dovitinib (TKI258) targets multiple receptor tyrosine kinases including Flt3, c-Kit, CSF1R, FGFR 1-4, VEGFR 1-3, and PDGFR alpha and beta, potentially resulting in decreased tumor growth (PMID: 15598814, PMID: 25219510, PMID: 23658459, PMID: 16033847). |
DrugClasses | CSF1R Inhibitor 28 FGFR Inhibitor (Pan) 26 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 VEGFR Inhibitor (Pan) 36 |
CAS Registry Number | 405169-16-6 |
NCIT ID | C76199 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Binimetinib + Dovitinib | Binimetinib Dovitinib | 1 | 0 |
Dovitinib | Dovitinib | 100 | 16 |
Dovitinib + E7449 | Dovitinib E7449 | 0 | 1 |
Dovitinib + Fluvoxamine | Dovitinib Fluvoxamine | 0 | 1 |
Dovitinib + Fulvestrant | Dovitinib Fulvestrant | 0 | 1 |
Dovitinib + Gemcitabine + Nab-paclitaxel | Dovitinib Gemcitabine Nab-paclitaxel | 0 | 1 |
Dovitinib + Trabectedin | Dovitinib Trabectedin | 1 | 0 |